论文部分内容阅读
目的:CP-154526是选择性促肾上腺皮质激素释放激素1型受体(CRFR1)拮抗剂,但其脱靶作用仍未阐述清晰。方法:本研究以CP-154526为研究对象,以化合物-蛋白相互组学为手段,构建其药物-药物网络并做数据挖掘。结果:DRAR-CPI实验结果显示CP-154526与23个药物相似,与抗肿瘤药物和抗感染药物相似较多,与治疗帕金森病Bromocripti最为相似。数据挖掘进一步分析发现CP-154526可与单胺氧化酶B有作用。结论:CP-154526可能具有抗肿瘤、抗感染等多方面脱靶作用,还可能通过单胺氧化酶B治疗帕金森病症。本研究为快速评价药物的全面疗效提供一种思路。
OBJECTIVE: CP-154526 is a selective corticotropin releasing hormone receptor type 1 (CRFR1) antagonist, but its off-target effects have not been elucidated yet. Methods: In this study, CP-154526 was used as the research object, and drug-drug network was constructed by means of compound-protein mutualomics and data mining was done. Results: The results of DRAR-CPI showed that CP-154526 was similar to 23 drugs, similar to anti-tumor drugs and anti-infective drugs, and most similar to Bromocripti in the treatment of Parkinson’s disease. Data mining further analysis found that CP-154526 with monoamine oxidase B role. CONCLUSION: CP-154526 may have antitumor, anti-infective and many other off-target effects and may also be used to treat Parkinson’s disease through monoamine oxidase B. This study provides a way to quickly evaluate the overall efficacy of drugs.